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nfections in homeless
. Krcmery
St. Elizabeth University College of Health and Social Sciences,
ratislava, Slovakia
Homeless people are frequent marginalised group of popula-
ion, especially in large cities. In the public and media, this group is
ssociated with transmission of communicable diseases, especially
uberculosis, scabies, skin and soft tissues infections (SSTI), sexu-
lly transmitted infections (STD), hepatitis A or B, and community
cquired methicillin-resistant Staphylococcus aureus (CA-MRSA).
We have reviewed systematically literature on infectious dis-
ases andhomeless or infectiousdiseases in shelterswithin last ﬁve
ears. In addition, our experience from 3 shelters, 2 low-attitude
nd 1 high-attitude shelters in Bratislava (Slovakia), with 0,5 mil
opulations, as well as from Almaty (Kazakhstan), Bishkek (Kyr-
yzstan) and Moscow (Russian Federation), with altogether 310
apacity of homeless shelters is reported.
Dominant infectious diseases in all 4 cities has been as follows:
STI 20 – 43%, respiratory tract infections (RTI) 15 – 55%, urogen-
tal tract infection and STD ≈ 32%, gastrointestinal tract infections
– 20%. Surprisingly, in shelters we have been running, no case of
uberculosis (TB) was found, despite other studies have revealed
B and inﬂuenza as commonest RTI in shelters for homeless.
oncerning antibiotic resistance respiratory isolates which have
een collected from sputum samples showed minimal number of
enicillin-resistant Pneumococci (PRP), MRSA and erythromycin-
esistant Streptococcus pyogenes. Most of the RTI have been caused
y susceptible pathogens.
Tuberculosis has been replaced by seasonal inﬂuenza and SSTI
s leading type of infectious diseases among homeless in shel-
ers inSlovakia,Kazakhstan,Kyrgyzstan,Russia.Antibiotic resistant
trains such asMRSA, PRP ormultidrug-resistant TB have been only
xceptionally found among studied population of homeless.
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nfectious diseases of street children in Nairobi, Kenya
.L. Timona Alumbasi
St. Kizita Orphanage; St. Raphael and St. Bakhita Clinic for Poor People,
airobi, Kenya
The street children phenomenon is an increasing problem in
ost cosmopolitan cities of the world. UNICEF estimates that there
re approximately 100million street childrenworldwide. In Africa,
bout 70% of population live belowpoverty line. Itwas estimated innfectious Diseases 16S (2012) e2–e157 e7
2007 that there were 250.000 – 300.000 children living and work-
ing on the streets across Kenya with more than 60.000 of them in
Nairobi.
Metanalysis of currently published studies on infectious dis-
eases in street children in large urban populations/cities of
Johannesburg, Lagos, Cairo and Calcutta are presented as well as
our own experiences from Nairobi.
Worldwide, street children are vulnerable to illnesses, diseases
and injuries, but tend to under-utilise health service. Bathing in
polluted rivers, scavenging among large trash piles, eating dirty
food, drinking contaminated water and sleeping outside with-
out mosquito nets – all of these increase risk of transmission of
infectious diseases among this population, particularly respira-
tory infections, skin infections, gastrointestinal tract infections and
malaria. Street children are also at high risk for getting infected
by sexually transmitted diseases, including HIV, due to multiple
sexual partners, low rate of condom use and having sex under the
inﬂuence of drugs and alcohol. Parasitosis, typhus and upper res-
piratory tract infections are the leading causes of morbidity among
street children in Nairobi.
Street children suffer from poor health outcomes because of
their lifestyle, living conditions and lack of access to medical and
social services. They depend on the existing public infrastructure as
pavements, public toilets and bathrooms. Improving them would
not only lead to a cleaner and more healthy urban environment,
but it would decrease health expenditure related to illnesses from
poorwaste disposal. The same should be done to improve the avail-
ability of clean and reliable drinking and washing water in urban
public kiosks. And the government of Kenya should provide free
health care for street children in public hospitals.
http://dx.doi.org/10.1016/j.ijid.2012.05.022
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Diagnostic challenges and interactive case histories
P.-R. Hsueh
National Taiwan University Hospital, Taipei, Taiwan, R.O.C
The role of ﬂuoroquinolones (FQs) as empirical therapy for
community-acquired pneumonia (CAP) remains controversial in
countries with high tuberculosis (TB) endemicity owing to the pos-
sibility of delayed TB diagnosis and treatment and the emergence
of FQ resistance in Mycobacterium tuberculosis. It is reported that
1–7% of CAP cases are re-diagnosed as pulmonary TB in Asian coun-
tries. A longer duration (≥7 days) of symptoms, a history of night
sweats, lack of fever (>38oC), infection involving the upper lobe,
presence of cavitary inﬁltrates, low total white blood cell count,
and the presence of lymphopenia are predictive of pulmonary TB.
Amongst patients with CAP who reside in TB-endemic countries
who are suspected of having TB, imaging studies as well as aggres-
sive microbiological investigations need to be performed early on.
It is important to differentiate between CAP and TB in the initial
presentation. If the lesion is located in the upper lung ﬁeld, clin-
ical specimen collection or rapid nucleic acid ampliﬁcation could
shorten the delay to TB diagnosis rather than restrict the empirical
treatment with FQs in CAP. If the lesion is in the lower lobe, risk
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actors including advanced age, prolonged duration of the lesion,
ack of fever and absence of air bronchograms should raise the sus-
icion of TB. Previous exposure to a FQ for >10 days in patients
ith TB is associated with the emergence of FQ-resistant M. tuber-
ulosis isolates. However, rates of M. tuberculosis isolates with
Q resistance are signiﬁcantly higher amongst multidrug-resistant
. tuberculosis isolates than amongst susceptible isolates. Conse-
uently, in countries with TB endemicity, a short-course (5-day)
egimen of a respiratory FQ is still recommended as empirical ther-
py for CAP patients if the patient is at low risk for TB.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.023
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luoroquinolones: A role in CAP and TB
. Grossman
Credit Valley Hospital, Mississauga, Canada
Fluoroquinolones are used widely for the treatment of LRTIs.
he ATS/IDSA guidelines for CAP recommended them as use-
ul choices in many clinical scenarios especially for hospitalized
atients. Concerns have been raised that using ﬂuoroquinolones
or the management of LRTIs will destroy the value of this class
or use particularly in MDR-TB. Arguments center on the notion
hat ﬂuoroquinoloneswillmask the clinical features of TB, delaying
iagnosis and enhancing widespread dissemination. They further
ostulate that the yield of culture-negative TB will increase and
hat, with increasing use of ﬂuoroquinolones, ﬂuoroquinolone-
esistant TB will become increasingly prevalent. Many patients
nfected with TB present with LRTI symptoms and a lung inﬁltrate.
brief treatment course with a ﬂuoroquinolone rarely produces a
apid clinical recovery. Most patients with TB, even when treated
ppropriately, have a very slow radiographic response and often
eteriorate initially. In contrast, bacterial pneumonia usually has
rapid radiographic response especially in previously healthy
oung adults. Studies trying to document delayed diagnosis when
uoroquinolones have been used, have been unable to mount a
ersuasive case. There is no evidence that patients initially treated
ith a ﬂuoroquinolone are more likely to have culture-negative
B. Multiple studies to date have documented a very low rate
f ﬂuoroquinolone-resistant TB throughout the world. There has
een no relationship between prior ﬂuoroquinolone exposure and
he emergence of resistance. The most persuasive relationship
s between ﬂuoroquinolone resistance and multi-drug resistance.
ndiandata suggest amorewidespreadproblemexists but thatmay
ave more to do with ease of availability of all antibiotics without
hysician supervision in that country. If a patient presents with
clinical illness suggestive of TB, ﬂuoroquinolones should not be
sed asmonotherapy. But even if used inpatients ultimately shown
o have TB, a short exposure to a potent ﬂuoroquinolone is unlikely
o delay diagnosis or lead to the emergence of bacterial resistance.
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Fluoroquinolones in TB: The future
S.H. Gillespie
University of St. Andrews, St. Andrews, United Kingdom
Moxiﬂoxacin has been demonstrated to have excellent activity
against Mycobacterium tuberculosis in vitro and in mouse models.
This encouraging activity against this important human pathogen
is combinedwith a pharmacokinetic proﬁle that permits once a day
dosing. The results of several mouse model studies have suggested
that substitution ofmoxiﬂoxacin for ethambutol or isoniazidmight
allow treatment duration to be shortened to four months. This has
been supported by clinical phase II studies.
A phase III pivotal trial (REMoxTB), is now underway to test reg-
imens built on moxiﬂoxacin and the results of these studies are
eagerly awaited. The test regimens substitute either ethambutol
or isoniazid with moxiﬂoxacin and offer the best chance of reduc-
ing current treatment duration from six months to four, the ﬁrst
improvement in TB treatment for more than ﬁfty years. The trial is
being performed at multiple sites in Africa and Asia.
Fluoroquinolonesalsohavean important role toplay in theman-
agementofpatientswithdrug toxicity aswell asbeingan important
part of the treatment ofmultiple drug resistance forwhich they are
recommended by a number of national and international bodies.
Nevertheless, well controlled clinical trials of the role of ﬂuoro-
quinolones are still required in the management of multiple drug
resistance are required. Further studies investigating regimens that
combine moxiﬂoxacin with repurposed and new agents are now
entering the clinical trial phase.
Resistance to ﬂuoroquinolones is a growing concern due to
the increasing frequency with which resistant strains are being
reported. This emphasises the importance of improving diagnosis
of respiratory tract infection, good antibiotic stewardship and the
use of the modern ﬂuoroquinolones that are least likely to select
for resistance.
http://dx.doi.org/10.1016/j.ijid.2012.05.025
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State of the science: Antiretroviral treatment for prevention
B. Hirschel
Geneva University Hospital, Geneva, Switzerland
“No virus, no transmission.” In the absence of treatment,
the viral load (the quantity of virus present in blood and sex-
ual secretions) is the strongest predictor of HIV transmission
with unprotected sex, or from infected mother to child. Effective
